Citations

Clear

381 citation(s) found for "Gross, MS".

Microsurgical Treatment of Intracranial Dural Arteriovenous Fistulas: A Collaborative Investigation From the Multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research
Raygor, Kunal P. , Abdelsalam, Ahmed , Raper, Daniel , Guniganti, Ridhima , Durnford, Andrew , Brinjikji, Waleed , Abecassis, Isaac Josh, Polifka, Adam , Samaniego, Edgar A. , Kwasnicki, Amanda , Potgieser, Adriaan R. E., Tada, Yoshiteru , Kansagra, Akash P. , Satomi, Junichiro, Eatz, Tiffany , Peterson, Eric C. , Starke, Robert M., Dijk, J. Marc C. van , Hayakawa, M. , Gross, Bradley A. , Fox, W. Christopher, Kim, Louis J. , Sheehan, Jason , Bulters, Diederik , Zipfel, Gregory J. , Abla, Adib A. , Alaraj, Ali , Eatz, Tiffany , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Tonetti, Daniel A. , Giordan, Enrico , Chen, Ching‐Jen , Levitt, Michael R. , Derdeyn, Colin P. , Chen, Stephanie , Peterson, Eric C., Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Lanzino, Giuseppe , Du, Rose , Lai, Pui Man Rosalind

Mayo Clinic

Neurosurgery | October 8, 2024 | Volume: 96 | Issue: 5 | Pages: 1023-1034

10.1227/neu.0000000000003204 | PMID 39471093 Get It

BACKGROUND AND OBJECTIVES: First-line therapy for most intracranial dural arteriovenous fistulas (dAVFs) is endovascular embolization, but some require microsurgical ligation due to limited endovascular accessibility, anticipated lower cure rates, or unacceptable risk profiles. We investigated the most common surgically treated dAVF locations and the approaches and outcomes of each. METHODS: The Consortium for Dural Arteriovenous Fistula Outcomes Research database was retrospectively reviewed. Patients who underwent dAVF microsurgical ligation were included. Patient demographics, angiographic information, surgical details, and postoperative outcomes were collected. The 5 most common surgically treated dAVF locations were analyzed about used surgical approaches and postoperative outcomes. Univariate analyses were performed with statistical significance set at a threshold of P < .05. RESULTS: In total, 248 patients in the Consortium for Dural Arteriovenous Fistula Outcomes Research database met inclusion criteria. The 5 most common surgically treated dAVF locations were tentorial, anterior cranial fossa (ACF), transverse-sigmoid sinus (TSS), convexity/superior sagittal sinus (SSS), and torcular. Most tentorial dAVFs were approached using a suboccipital, lateral supracerebellar infratentorial approach (39.3%); extended retrosigmoid approach (ERS) (25%); or posterior subtemporal approach (19.6%). All ACF dAVFs used a subfrontal approach; 5.3% also included an anterior interhemispheric approach. Most TSS dAVFs were ligated via ERS (31.3%) or subtemporal (31.3%) approaches. All convexity/SSS dAVFs used an interhemispheric approach. All torcular dAVFs used the suboccipital, lateral supracerebellar infratentorial approach, with 10.5% undergoing simultaneous ERS craniotomy. Angiographic occlusion rates after microsurgery were 85.5%, 100%, 75.8%, 79.2%, and 73.7% for tentorial, ACF, TSS, convexity/SSS, and torcular dAVFs, respectively ( P = .02); the permanent neurological complication rates were 1.8%, 2.6%, 9.1%, 0%, and 0% ( P = .31). There were no statistically significant differences in development of complications ( P = .08) or Modified Rankin Scale at the last follow-up ( P = .11) by fistula location. CONCLUSION: Although endovascular embolization is the first-line treatment for most intracranial dAVFs, surgical ligation is an important alternative. ACF and tentorial fistulas particularly demonstrate high rates of postoperative obliteration.
Assessing Professionalism in Early Medical Education: Experience with Peer Evaluation and Self-evaluation in the Gross Anatomy Course
Bryan, RE, Carmichael, S. W., Viggiano, T R, Pawlina, Wojciech, Krych, Aaron J.

Mayo Clinic

Annals of the Academy of Medicine, Singapore | September 20, 2024 | Volume: 34 | Issue: 8 | Pages: 486-491

10.47102/annals-acadmedsg.v34n8p486 Get It

Introduction: As today’s healthcare model moves toward more streamlined and corporate industrialism, it is our responsibility, as doctors, to ensure the integrity of medicine’s foundation in professionalism. The erosion of professional values not only creates a climate of animosity, but reverberates negatively to impact the development of students, who model their behaviour after those they most respect. This hazard has spurred an evaluation of medical school curricula, with a new emphasis on professionalism in the philosophy of medical education. Courses such as Gross Anatomy that, in the past, offered “pure content,” are now being used to teach and evaluate professionalism. The goal of this study was to determine if peer evaluation and self-evaluation used in conjunction and implemented early in the medical curriculum, can serve as useful tools to assess and provide feedback regarding professional behaviour in first-year medical students. Materials and Methods: From 1999 to 2003, students at Mayo Clinic College of Medicine evaluated themselves and their peers during the Gross and Developmental Anatomy Course. Numerical evaluations and written comments were statistically analysed within established categories of professionalism and correlated with academic performance, gender, and peer rating and self-rating. Results: The majority of written comments pertained to inter-professional respect, responsibility, and excellence. Students who gave higher peer evaluation and selfevaluation scores provided more positive comments, and students performing well in the course provided more positive comments about their peers and themselves than did those struggling academically. Students consistently rated their peers higher than themselves, and male students rated themselves higher than did female students. Conclusions: Implementing peer evaluation and self-evaluation early in the medical curriculum is a valuable exercise in teaching first-year medical students assessment skills when evaluating their behaviour, as well as the behaviour of their colleagues.
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Sundby, R. Taylor , Szymanski, Jeffrey J. , Pan, Alexander , Jones, Paul A. , Mahmood, Sana , Reid, Olivia H. , Srihari, Divya , Armstrong, Amy E. , Chamberlain, Stacey , Burgic, Sanita , Weekley, Kara , Murray, Béga , Patel, S. G. , Qaium, Faridi , Lucas, Andrea N. , Fagan, Margaret , Dufek, Anne , Meyer, Christian F. , Collins, Natalie B. , Pratilas, Christine A. , Gross, Andrea M. , Widemann, Brigitte C. , Chaudhuri, Aadel A. , Pan, Alexander C , Mahmood, Sana Z , Patel, Sneh , Dombi, Eva , Gross, Andrea M , Kim, AeRang , Chrisinger, John S A , Dehner, Carina A , Widemann, Brigitte C , Hirbe, Angela C , Chaudhuri, Aadel A , Shern, Jack F , Sundby, R. Taylor , Collins, Natalie B , Dombi, Eva , Kim, AeRang , Chrisinger, John S.A. , Dehner, Carina , Hirbe, Angela C. , Shern, Jack F.

Mayo Clinic

Clinical Cancer Research | August 2, 2024 | Volume: 30 | Issue: 19 | Pages: 4363-4376

10.1158/1078-0432.ccr-24-0797 | PMID 39093127 Get It

Abstract Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe a cell-free DNA (cfDNA) fragmentomic approach that distinguishes nonmalignant, premalignant, and malignant forms of PNST in the cancer predisposition syndrome, NF1. Experimental Design: cfDNA was isolated from plasma samples of a novel cohort of 101 patients with NF1 and 21 healthy controls and underwent whole-genome sequencing. We investigated diagnosis-specific signatures of copy-number alterations with in silico size selection as well as fragment profiles. Fragmentomics were analyzed using complementary feature types: bin-wise fragment size ratios, end motifs, and fragment non-negative matrix factorization signatures. Results: The novel cohort of patients with NF1 validated that our previous cfDNA copy-number alteration–based approach identifies malignant PNST (MPNST) but cannot distinguish between benign and premalignant states. Fragmentomic methods were able to differentiate premalignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Conclusions: Novel cfDNA fragmentomic signatures distinguish AN from benign plexiform neurofibromas and MPNST, enabling more precise clinical diagnosis and management. This study pioneers the early detection of malignant and premalignant PNST in NF1 and provides a blueprint for decentralizing noninvasive cancer surveillance in hereditary cancer predisposition syndromes.
ATRT-08. ATYPICAL TERATOID RHABDOID TUMOR IN AN ADULT PATIENT WITH DOWN SYNDROME
Judd, Dallin, Almefty, Kaith K. , Vern-Gross, T.Z., Hoffman, Lindsey M. , Tiwari, Nishant , Vaughn, Jennifer, Mangum, Ross

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.008 Get It

Abstract BACKGROUND Atypical teratoid/rhabdoid tumor (ATRT) is a malignant, highly aggressive embryonal tumor of the central nervous system. Long-term survival remains dismal despite aggressive multimodal therapy, including a maximal safe surgical resection and intensive systemic chemotherapy +/- radiation therapy. While these tumors typically present in infancy or early childhood, there are scattered case reports of adult-onset ATRT. Making prognostic conclusions or therapeutic decisions for this older patient population remains challenging due to the paucity of these reports. CASE REPORT A 25-year-old female with Down syndrome presented with nausea, vomiting, dysphagia, and facial droop and was found to have an avidly enhancing, left cerebellopontine angle mass. There was initial clinical suspicion for leukemic chloroma given the patient’s Down syndrome status and known association with higher rates of hematologic malignancy concurrent with a dramatic scarcity of solid tumors in the Down syndrome population. However, histology demonstrated sheets of high-grade rhabdoid cells with loss of INI1 expression, pathognomonic for ATRT. Further sequencing defined a frameshift mutation in SMARCB1 (p.C298), and methylation profiling matched with high confidence to the MYC subclass of ATRT. The patient was treated with subtotal surgical resection and focal proton radiation, followed by chemotherapy on a modified regimen based on the Children’s Oncology Group protocol, ACNS0333. Systemic methotrexate and all consolidative high-dose chemotherapy with stem cell rescue were omitted due to concern for heightened risk of treatment-related toxicity. The patient remains alive and clinically asymptomatic 19 months from diagnosis. CONCLUSION This report represents the first known case of ATRT in an adult patient with Down syndrome, offering unique mechanistic insight into the tumorigenesis of ATRT. Adult ATRT is a rare entity without standardized treatment or established prognostic understanding. Further studies are needed to define an appropriate risk-adapted therapeutic approach for this patient population.
Patterns of cognitive domain abnormalities enhance discrimination of dementia risk prediction: The ARIC study
Pike, James Russell , Sharrett, A. Richey, Windham, B. Gwen , Sullivan, Kevin , Albert, Marilyn , Yaşar, Sevil , Burgard, Sheila , Gross, Alden L. , Sullivan, Kevin J , Pike, James R , Knopman, David S. , Gottesman, Rebecca F. , Mosley, Thomas H. , Walker, Keenan A. , Li, David D.-U.

Mayo Clinic

Alzheimer's & Dementia | June 15, 2024 | Volume: 20 | Issue: 7 | Pages: 4559-4571

10.1002/alz.13876 | PMID 38877664 Get It

AbstractINTRODUCTIONThe contribution of neuropsychological assessments to risk assessment for incident dementia is underappreciated.METHODSWe analyzed neuropsychological testing results in dementia‐free participants in the Atherosclerosis Risk in Communities (ARIC) study. We examined associations of index domain–specific neuropsychological test performance with incident dementia using cumulative incidence curves and Cox proportional hazards models.RESULTSAmong 5296 initially dementia‐free participants (mean [standard deviation] age of 75.8 [5.1] years; 60.1% women, 22.2% Black) over a median follow‐up of 7.9 years, the covariate‐adjusted hazard ratio varied substantially depending on the pattern of domain‐specific performance and age, in an orderly manner from single domain language abnormalities (lowest risk) to single domain executive or memory abnormalities, to multidomain abnormalities including memory (highest risk).DISCUSSIONBy identifying normatively defined cognitive abnormalities by domains based on neuropsychological test performance, there is a conceptually orderly and age‐sensitive spectrum of risk for incident dementia that provides valuable information about the likelihood of progression.Highlights Domain‐specific cognitive profiles carry enhanced prognostic value compared to mild cognitive impairment. Single‐domain non‐amnestic cognitive abnormalities have the most favorable prognosis. Multidomain amnestic abnormalities have the greatest risk for incident dementia. Patterns of domain‐specific risks are similar by sex and race.
A world-wide study on delirium assessments and presence of protocols
Nydahl, Peter , Liu, Keibun , Bellelli, Giuseppe , Calle, Gabi Heras-La, Hoffmann, Magdalena , Jeitziner, Marie‐Madlen , Krewulak, Karla D. , Paulino, Maria Carolina , Haken, Rebecca von , Group, the WDAD Study, Abdalgany, Ahmed Gaber Ahmed, Aburaas, Amjad, Albakosh, Bashir Abobaker, Alhamdan, Hamza Ismail Ahmad, Aljbali, Akram Waled Rajab M, Al-Kandari, Fareeda, Anders, Daniel, Anderson, Marsali, Ashkenazy, Shelly , Avelino, Thiago, Bail, Kasia , Bakri, Ashraf , Baroum, Alaa Mohamed Ali , Brendt-Müller, Jennifer, Brobeil, Angelika, Byrnes, Tru , Cahill, Maria, Canelas, Maria Ana , Carroll, Ida, Conley, Amy, Cotton, Shannon A. , Couser, Mandy, Salgado, A., Cusworth, Elizabeth, Cvoro, Vera , Deosaran, Jordanna, Diebels, Merel, Docherty, Elaine A, Dossow, Vera von , Drennan, Megan, Egdeer, Akram Amin, Eichelsheim, Patrick, Elagili, Aissha Ali Saleh, Elsahl, Saifaleslam Jamal, Elshaikh, Hajer Alsadeg Mohammed, Fathi, Azza , Feige, Melanie, Fiest, Kirsten M. , Fong, Marleta Irene Joy, Fuchita, Mikita , Gaffney, Carol, Vich, Carola Giménez-Esparza, Feldmann, Nicole , Fitzpatrick, Neasa , Fong, Marleta Irene Joy, Goldberg, María Adela , Golüke, Nienke M.S. , Graaf, Marinette van der , Groenewald, Engelina , Gross, Renate , Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai Ahmad Hasan, Hamida, Bahaeddin Ben, Hamza, Monalyce, Hopkins, Jane , Hopkins, John , Jeyaseelan, Arveen , Kadhim, Ali Jawad, Kohler, S., Kooken, Rens , Khutwah, Ayman Salim Abu, Lange, Puck, Liefrink, Sharon, Lin, Yu‐Min , Loo, Shi Pei , Rodrigues, Sara Beatriz Lopes, MacDonald, Allan S., Madders, G, Massaro, Claudia, Maya, Kerri, Manioudaki, Sofia, Stewart, McKenna, Coimbra, Isabel , Miranda, Teresa, Mohamed, Mohamed A. , Mohammed, Mushin Mohammed Elhadi Agbna, Naeem, Fariha , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Noonan, Claire, Lopes, Maria Inês, Otmani, Zina , O’Reilly, Susan, Ozorio, Valerie, Palakashappa, Jessica, Pandya, Tej , Papadea, Panagiota, Papanikolaou, Metaxia, Pinardi, Elena , Pereira, Inês Filipa Pinto, Premathilaka, Chirantha , Pop‐Purceleanu, Monica , Puchegger, Marlene, Qalhoud, Nouralddeen Mohammed, Raasing, Maike, Ragheb, Dalia Talaat, Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Schimböck, Florian , Schmädig, Roman , Schoon, Yvonne , Sethia, Deepak , Sextl, Edith, Shah, Bhagyesh , Shaout, Dua’a, Sharabi, Alaa Fouad, Shields, Lynn, Smith, Kendall A. , Dam, Linda Smulders-van, Soiza, Roy L. , Spiegler, Andrea, Stocks, Lucy, Sumerauer, Stefan, Tam, Stephanie , Tan, Aik Haw, Tohsche, Peter, Torres, Raquel Gouveia, Toth, Chantal, Tousgaard, Iben, Vogt, Birgit, Walsh, Erica M., Ward‐Stockham, Kristel , Mart, Melinda Webb‐St, Wijnen-Meijer, Mariajne Elisabeth, Zastrow, Inke , Nydahl, Peter , Jeitziner, Marie-Madlen , Krewulak, Karla D , Benbenishty, Julie Sarah , Boogaard, Mark van den , Caplan, Gideon A. , Chung, Chi Ryang , Elhadi, Muhammed , Gurjar, Mohan , Mailhot, Tanya , Morandi, Alessandro , Nawa, Ricardo Kenji , Oh, Esther S , Collet, Marie Oxenbøll , Lindroth, Heidi , Group, the WDAD Study, Abdelmohsen, Sarah Magdy , Aggar, Christina , Alkandari, Farah, Alkaseek, Akram Mohammed , Anders, Daniel, Anderson, Marsali, Blackwood, Bronagh , Brendt-Müller, Jennifer , Burke, Richard, Cacciatore, Stefano , Cahill, Maria, Conley, Amy, Costello, Maria , Diebels, Merel, Elshaikh, Hajer Alsadeg Mohammed, Emme, Christina , Exl, Matthias Thomas , Fong, Marleta Irene Joy, Gaffney, Carol, Fitzgerald, Rachel, Fong, Marleta Irene Joy, Graaf, Mirjam, Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai, Hetland, Breanna , Hopkins, Jane Adele, Ibrahim, Said A. , Imbrìaco, Guglielmo , Inoue, Shigeaki , Kadhim, Ali Jawad, Kohler, Sabrina, Korompeli, Anna , Krüger, Lars , Lange, Puck, Rodrigues, Sara Beatriz Lopes, MacDonald, Allan, McAndrew, Natalie S. , Mohamed, Mohamed Anwar Abdelsalam, Mohammed, Mushin Mohammed Elhadi Agbna, Mulkey, Malissa , Nakamura, Kensuke , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Olotu, Cynthia , Ornago, Alice Margherita , O’Reilly, Susan, Penfold, Rose , Pereira, Inês Filipa Pinto, Quinn, Terence J , Raasing, Maike Wm, Rajhans, Prasad Anant , Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Salis, Francesco , Sharabi, Alaa Fouad, Smith, Kendall, Tam, Stephanie, Timmons, Suzanne , Torres, Raquel Gouveia, Tsolaki, Vasiliki , Castro, Roberta Esteves Vieira de , Vogt, Birgit, Walsh, Erica, Wefer, Franziska , Wøien, Hilde , Zazzara, Maria Beatrice

Mayo Clinic

Age and Ageing | June 12, 2024 | Volume: 53 | Issue: 7 | Pages: No page available

10.1093/ageing/afae129 | PMID 38952186 Get It

Abstract Background Delirium is a common complication of older people in hospitals, rehabilitation and long-term facilities. Objective To assess the worldwide use of validated delirium assessment tools and the presence of delirium management protocols. Design Secondary analysis of a worldwide one-day point prevalence study on World Delirium Awareness Day, 15 March 2023. Setting Cross-sectional online survey including hospitals, rehabilitation and long-term facilities. Methods Participating clinicians reported data on delirium, the presence of protocols, delirium assessments, delirium-awareness interventions, non-pharmacological and pharmacological interventions, and ward/unit-specific barriers. Results Data from 44 countries, 1664 wards/units and 36 048 patients were analysed. Validated delirium assessments were used in 66.7% (n = 1110) of wards/units, 18.6% (n = 310) used personal judgement or no assessment, and 10% (n = 166) used other assessment methods. A delirium management protocol was reported in 66.8% (n = 1094) of wards/units. The presence of protocols for delirium management varied across continents, ranging from 21.6% (on 21/97 wards/units) in Africa to 90.4% (235/260) in Australia, similar to the use of validated delirium assessments with 29.6% (29/98) in Africa to 93.5% (116/124) in North America. Wards/units with a delirium management protocol [n = 1094/1664, 66.8%] were more likely to use a validated delirium test than those without a protocol [odds ratio 6.97 (95% confidence interval 5.289–9.185)]. The presence of a delirium protocol increased the chances for valid delirium assessment and, likely, evidence-based interventions. Conclusion Wards/units that reported the presence of delirium management protocols had a higher probability of using validated delirium assessments tools to assess for delirium.
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Weinstein, Gregory S., Mehra, Ranee , García, Joaquín J. , Kim, Seungwon , O’Malley, Bert W. , Özer, Enver , Koch, Wayne M. , Morris, Luc, Smith, Russell K., Karakla, Daniel W., Burtness, Barbara , Flamand, Yael , Quon, Harry , Gross, Neil D , Bell, R. Bryan , Patel, Mihir R , Lango, Miriam N. , Richmon, Jeremy D. , Holsinger, F. Christopher , Ferris, Robert L.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 6009-6009

10.1200/jco.2024.42.16_suppl.6009 Get It

6009 Background: E3311 is a phase II trial of TOS by credentialed surgeons with pathology-driven deintensified post-operative management in HPV+ OPC. Intermediate risk patients were randomized between standard and reduced dose radiation. We present mature outcome data, at median follow up of 52.4 months (m). Methods: Patients were eligible who had resectable cT1-2 stage III/IV AJCC7 p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (Arm A, N=38); those with clear margins, 2-4 + LN, or ENE ≤1mm were randomized to 50Gy (Arm B, N=100) or 60Gy (Arm C, N=108); those with involved margins, >4 + LN, or >1mm ENE received weekly cisplatin 40 mg/m2 and 60-66Gy (Arm D, N=113). Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared using a log-rank test, stratified by arm for comparisons of primary site and smoking history. Results: Among 359 evaluable patients, 54-m PFS and OS were 90.6% (90% CI: 87.2%, 93.1%) and 95.3% (90% CI: 93.0%, 96.9%). 54-m PFS by arm was: A 93.2% (90% CI: 79.6%, 97.8%); B 94.9% (90% CI: 89.7%, 97.5%); C 90.2% (90% CI: 82.7%, 94.6%) and D 85.5% (90% CI: 77.5%, 90.8%). 54-m OS by arm was: A 97.1% (90% CI: 85.7%, 99.4%); B 97.9% (90% CI: 93.5%, 99.3%), C 95.1% (90% CI: 90.1%, 97.6%) and D 92.5% (90% CI: 86.9%, 95.7%). Among patients in Arm A, 11 had N0 and 27 N1 stage. Median Arm A lymph node yield (LNY) was 29 (11 to 91 LN) and did not differ for patients with/without recurrence (p=0.83). All Arm A recurrences were in N1 patients: 1 at 18 m and 3 at > 40 m. No significant difference in PFS or OS was observed by prescribed radiation dose for intermediate risk patients (Arm B vs. C). Outcome did not differ by primary site of tonsil vs. other OPC (oOPC): 54-m PFS Tonsil 89.3% (90% CI: 84.9%, 92.5%) vs. oOPC 92.9% (90% CI: 87.0%, 96.2%), p=0.28, and 54-m OS Tonsil 94.6% (90% CI: 91.5%, 96.6%) vs oOPC 96.6% (90% CI: 92.4%, 98.5%), p=0.35. Smoking history also did not impact outcome. 54-m PFS was 89.9% (90% CI: 85.9%, 92.9%) for those with ≤10 pack-years (PY) tobacco exposure and 91.7% (90% CI: 83.9%, 95.9%) for those with >10 PY. Conclusions: TOS, neck dissection with deintensified risk-based post-operative management results in outstanding 54-m PFS and OS across all subsites of T1-2 p16+ OPC, irrespective of smoking history. Late recurrence is not increased when post-operative radiation is reduced from 60 to 50Gy for intermediate risk patients. Pathologic >1mm ENE (N=87), involved margin (N=12) or >4 involved LN (N=30) accurately identify patients at increased recurrence risk and outcomes were favorable among such patients. Among patients with favorable pathologic characteristics, a subset with N1 disease are at risk for late recurrence and further characterization of these patients is warranted. Clinical trial information: NCT01898494 .
Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam, Gita , Bhatnagar, Vishal , Diamond, Matthew, Jones, Lee , Power, Bradford, Ruddy, Kathryn J. , Tarver, Michelle E. , Gross, Cary P. , Dueck, Amylou C. , Brown, Abbie, Cathcart-Rake, Elizabeth , Diamond, Matthew, Faust, Louis , Fiero, Mallorie H. , Huntington, Scott F. , Jeffery, Molly Moore , Paludo, Jonas , Ross, Joseph S. , Mougalian, Sarah S. , Wood, William A. , Kluetz, Paul Gustav

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1564-1564

10.1200/jco.2024.42.16_suppl.1564 Get It

1564 Background: Physical function (PF) is a core outcome in cancer trials that can inform treatment tolerability. PF can be assessed across modalities including by patient (pt) report, clinician (clin) report, performance tests and digital sensors. The optimal approach for PF measurement has not been defined. Methods: In4M is a prospective observational study evaluating PF in pts initiating chemotherapy for breast cancer or lymphoma followed over 9 months. We used an electronic platform (Hugo) to aggregate serially assessed pt-reported PF, clin- and pt-reported ECOG performance status (PS), 6-minute walk test (6MWT) and wearable (Fitbit) data. We evaluated feasibility in all pts; associations among PF measures and the ability of PF measures to detect change were evaluated in pts with both baseline (BL) and 3-month (3M) data. We used Pearson correlations to assess the relationship of average daily steps with measures of PF. To assess change, we compared each PF measure from BL to 3M using a 2-sided α=.05 paired t-test. Results: Of the208 pts enrolled, 193 (93%) and 159 (76%) completed surveys, and 121 (58%) and 124 (60%) provided wearable data (evaluable: ≥1 day data) at BL and 3M, respectively. When requiring a stringent BL with 4+ days of data with ≥1 weekend day to be evaluable, 88 (42%) and 120 (58%) provided wearable data at BL and 3M. At both BL and 3M, pt-reported PF was generally more highly correlated with wearable-derived daily steps than clin-reported PF and 6MWT were (Table). Significant declines in PF were observed for pt- and clin-reported PF (all p<0.05), but not other modalities. Conclusions: Longitudinalassessment of multi-modal PF data including pragmatic wearable data collection was feasible in pts receiving chemotherapy. Pt-reported PF was the only modality that was both correlated with step count and able to detect change. Additional wearable metrics, correlations among PF measurements and outcomes, and clinically meaningful change scores will be reported. Optimal PF measurement may improve future reporting of treatment tolerability. Clinical trial information: NCT05214144 . [Table: see text]
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Soulos, Pamela R. , Ruddy, Kathryn J. , Lerro, Catherine C. , Graham, David J. , Liberatore, Mark, Rivera, Donna R. , Jairam, Vikram , Gross, Cary P. , Baum, Laura Van Metre , KC, Madhav , Jeffery, Molly Moore , Lee, Hana , Leapman, Michael , Dinan, Michaela A. , Park, Henry S.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11059-11059

10.1200/jco.2024.42.16_suppl.11059 Get It

11059 Background: Some opioid stewardship policies could negatively affect patients with cancer pain. However, patients with cancer are also at risk for opioid related harms, especially with persistent use. We assessed opioid prescribing trends in the context of cancer treatment and patient reported pain in a large health system in Connecticut. Methods: We conducted a retrospective cohort study of opioid-naïve adult patients with solid tumor malignancies diagnosed from 2016 through 2020 within the Yale New Haven Health System. We identified new (≥1 opioid prescription in 0-6 months following diagnosis) and additional (0-6 and 6-9 months) opioid prescriptions. The analysis evaluated all eligible patients as well as two clinical cohorts: patients treated surgically and patients with metastatic cancer. For patients with metastatic cancer and a documented pain score in the electronic health record flowsheet data, we further stratified by any (any score≥1) or no (all scores=0) pain in the 6 months since diagnosis and prior to first opioid, if given. For these patients, we noted therapeutic class of the first opioid. We used a logistic model adjusted for patient demographics to calculate predicted probability of opioid prescription and change over time. Results: A total of 10,868 patients met study criteria. Overall, we observed a decline in new opioid prescribing from 69.0% to 62.7% (p<.001) (Table). Additional opioid use also declined from 23.4% to 20.2% (p=.02). In the surgery cohort, new opioid prescribing fell from 95.7% to 88.2% (p<.001), while additional opioid use was stable over time (approximately 12%). For patients with metastatic cancer with any documented pain, new opioid prescribing was stable over time (approximately 56%). For those with documented pain scores=0, new opioid prescribing declined from 59.7% to 34.2% (p<.001). In these patients, the class listed on the first opioid prescription was analgesia in 86.6% and cough in 13.4%. Conclusions: Overall, and in patients treated with oncological surgeries, our study in a single large US health system suggests a modest, gradual decline in opioid prescribing for patients with cancer over time. On the other hand, among patients with metastatic cancer, opioid prescribing remained stable for those with documented pain and declined steeply for those without documented pain. [Table: see text]
Management of failed flow diversion for intracranial aneurysm beyond the first 6 months of follow-up: an international Delphi consensus
Chintapalli, Renuka , Nguyen, Sarah, Dammann, Philipp , Raygor, Kunal P. , Ogilvy, Christopher S. , Linfante, Italo , Almefty, Rami O. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Starke, Robert M. , Gross, Bradley A. , Kan, Peter, Coulthard, Alan , Dabus, Guilherme , Raper, Daniel , Kilburg, Craig , Abla, Adib A. , Abla, Adib , Ogilvy, Christopher S , Burkhardt, Jan‐Karl , Nguyen, Sarah E. , Taussky, Philipp , Grandhi, Ramesh , Tonetti, Daniel A. , Andersson, Tommy , White, Phil , Chapot, René , Fox, W Christopher , Tawk, Rabih G. , Lanzino, Giuseppe , Hanel, Ricardó A. , Jadhav, Ashutosh P. , Hassan, Ameer E , Mascitelli, Justin R , Fargen, Kyle M , Levitt, Michael R. , Jabbour, Pascal , Gross, Bradley , Killer-Oberpfalzer, Monika , Rautio, Riitta , Dmytriw, Adam A. , Dabus, Guilherme C. , Deuschl, Cornelius , Budohoski, Karol P.

Mayo Clinic

Journal of Neurosurgery | June 1, 2024 | Volume: 141 | Issue: 5 | Pages: 1225-1234

10.3171/2024.3.jns2499 | PMID 38820616 Get It

OBJECTIVE The placement of flow-diverting devices has become a common method of treating unruptured intracranial aneurysms of the internal carotid artery. The progressive improvement of aneurysm occlusion after treatment—with low complication and rupture rates—has led to a dilemma regarding the management of aneurysms in which occlusion has not occurred within 6–24 months. The authors aimed to identify clinical consensus regarding management of intracranial aneurysms displaying persistent filling 6–24 months after flow diversion and to ascertain questions that may drive future investigation. METHODS An international panel of 67 experts was invited to participate in a multistep Delphi consensus process on the treatment of intracranial aneurysms after failed flow diversion. RESULTS Of the 67 experts invited, 23 (34%) participated. Qualitative analysis of an initial survey with open-ended questions resulted in 51 statements regarding management of aneurysms showing persistent filling after flow diversion. The statements were grouped into 8 categories, and in the second round, respondents rated the degree of their agreement with each statement on a 5-point Likert scale. Flow diverters with surface modifiers did not influence administration of dual-antiplatelet therapy according to 83%. Consensus was also reached regarding the definition of treatment failure at specific time points, including at 6 months if there is aneurysm growth or persistent rapid flow through the entirety of the aneurysm (96%), at 12 months if there is aneurysm growth or symptom onset (78%), and at 24 months if there is persistent filling regardless of size and filling characteristics (74%). Although experts agreed that the degree of intimal hyperplasia or in-device stenosis could not be ascertained by noninvasive imaging alone (83%), only 65% chose digital subtraction angiography as the preferred modality. At 6 and 12 months, retreatment is preferred if there is persistent filling with aneurysm growth (96%, 96%), device malposition (48%, 87%), or a history of subarachnoid hemorrhage (65%, 70%), respectively, and at 24 months if there is persistent filling without reduction in aneurysm size (74%). Experts favored treatment with an additional flow diverter (87%) over aneurysm clipping, applying the same principles for follow-up (83%) and treatment failure (91%) as for the first flow diverter. CONCLUSIONS The authors present the consensus practices of experts in the management of intracranial aneurysms without occlusion 6–24 months after treatment with a flow-diverting device.